Advanced

Monitoring of human papillomavirus vaccination.

Dillner, Joakim LU ; Arbyn, M; Unger, E and Dillner, Lena LU (2011) In Clinical and Experimental Immunology Dec. p.17-25
Abstract
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be... (More)
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical and Experimental Immunology
volume
Dec
pages
17 - 25
publisher
British Society for Immunology
external identifiers
  • wos:000284851800003
  • pmid:21062269
  • scopus:78649721287
ISSN
0009-9104
DOI
10.1111/j.1365-2249.2010.04268.x
language
English
LU publication?
yes
id
163958b9-0d5e-486f-8a58-2da97227028e (old id 1732139)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21062269?dopt=Abstract
date added to LUP
2010-12-01 10:52:35
date last changed
2017-02-19 04:23:31
@article{163958b9-0d5e-486f-8a58-2da97227028e,
  abstract     = {Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.},
  author       = {Dillner, Joakim and Arbyn, M and Unger, E and Dillner, Lena},
  issn         = {0009-9104},
  language     = {eng},
  pages        = {17--25},
  publisher    = {British Society for Immunology},
  series       = {Clinical and Experimental Immunology},
  title        = {Monitoring of human papillomavirus vaccination.},
  url          = {http://dx.doi.org/10.1111/j.1365-2249.2010.04268.x},
  volume       = {Dec},
  year         = {2011},
}